Form 4: Amgen CEO Robert Bradway Reports Acquisition of Shares and Dividend Equivalents

Amgen's CEO, Robert Bradway, reported the acquisition of common stock and dividend equivalents, along with holdings in grantor retained annuity trusts (GRATs).

Summary

• Robert A. Bradway, CEO, President, and Chairman of Amgen, filed a Form 4 detailing changes in beneficial ownership of Amgen stock.
• On March 3, 2025, Bradway acquired 25,734 shares of Amgen common stock.
• These shares were acquired at $0, likely indicating a grant or award.
• Bradway directly owns 599,925 shares of Amgen common stock following the transaction.
• Bradway also indirectly owns 90,000 shares through a GRAT and another 90,000 shares through a spousal GRAT.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of shares by the CEO is generally a positive sign, but it's part of a compensation package.

Positives

• The CEO's acquisition of shares could be interpreted positively, signaling confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Executive compensation packages often include stock grants and options to align management's interests with those of shareholders, which is a common practice among large pharmaceutical companies like Pfizer, Johnson & Johnson, and Merck.
• The use of GRATs is a common estate planning technique employed by high-net-worth individuals, including executives at companies like Apple and Microsoft, to transfer assets while minimizing gift tax implications.

Stakeholder Impact

• The CEO's stock ownership aligns his interests with shareholders.
• The filing provides transparency to investors regarding insider transactions.

Key Dates